- What: Eisai engages in collaborative R&D and intellectual property sharing that addresses the needs of people in low- and middle-income countries.
- Details: This is supported by Eisai’s World Health Initiative, which presents a clear framework for engaging in product development partnerships.
- Impact: Eisai states that its World Health Initiative has proven itself as a model for product development that can attain corporate goals and objectives towards Global Health.
- Scope: The collaborative approach applies to its entire pipeline of products for diseases in scope, with a focus on malaria, TB and neglected tropical diseases.
Background and overview
Eisai’s World Health Initiative, established in 2012, presents a clear approach to engaging in product development partnerships. Under this model, the company develops internal assets or assets discovered externally through a framework of product development partnerships. According to the company, the World Health Initiative “has proven to be a new business strategy and model for product development that can attain corporate goals and objectives towards Global Health.” The company’s approach is demonstrated with action, as measured by the Access to Medicine Index 2016 R&D Technical Area.
Compared to its peers, Eisai is conducting the highest proportion of its R&D projects through partnerships. It has R&D partnerships in all its disease areas, except epilepsy, covering 86% of its pipeline for high-burden diseases. Relative to its peers, a high proportion – two thirds – of these partnerships are based on terms for increasing access.
Eisai partners with organisations such as Drugs for Neglected Diseases Initiative and the Sabin Institute. It has eight active partnerships that fall under Grant Agreements with the Global Health Innovative Technology Fund. These agreements stipulate that products should be available for developing countries with reasonable price or licensed-out with royalty-free, and that data and should be published and shared broadly.
Eisai ranks 1st among the 20 companies measured in the Index in terms of sharing intellectual property with research institutions or drug discovery initiatives to facilitate R&D. Eisai shares intellectual property with partners such as the Wellcome Trust, Medicines for Malaria Venture, Macrofilaricide Drug Accelerator and WIPO Re:Search.
Eisai publishes its R&D activities, including partnerships, that have access to medicine objectives on its website.